Skip to main content
. 2022 Aug 24;88(17):e00806-22. doi: 10.1128/aem.00806-22

FIG 6.

FIG 6

Anticancer activities (IC50) of compounds 1 to 3. (A) Bioevaluation of compounds 1 to 3 against the human lung cancer cell line A549. (B) Bioevaluation of compounds 1 to 3 against the human cervical cancer cell line HeLa. (C) Bioevaluation of compounds 1 to 3 against the human colon cancer cell line HCT116.